Company intelligence / Profile preview

Navrogen

Cheyney, Pennsylvania, United Statesnavrogen.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Navrogen has developed a proprietary platform focused on overcoming tumor-induced suppression of the humoral immune response. The company’s lead programs target novel HIO factors with antibody-based therapies, including ADCs. As of May 2025, its pipeline remains in preclinical or IND-enabling stages; no clinical trial results have been published yet. Recent financing rounds support advancement toward first-in-human studies.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Diagnostic assaysImmuno-oncology agents
Industry: Biotech

Drug pipeline

8 assets

NAV-006

Preclinical

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Navrogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navrogen.

Explore the full profile